Extracellular vesicles could be personalized drug delivery vehicles

March 12, 2018, Pennsylvania State University
Ligands-grafted extracellular vesicles as drug delivery vehicles. Credit: Xin Zou

Creating enough nanovesicles to inexpensively serve as a drug delivery system may be as simple as putting the cells through a sieve, according to an international team of researchers who used mouse autologous—their own—immune cells to create large amounts of fillable nanovesicles to deliver drugs to tumors in mice.

Nanovesicles are tiny sacs released by cells that carry chemical messages between cells. These nanovesicles are natural delivery vehicle and useful in for .

"Currently, natural nanovesicles can be harvested from cell culture supernatant (the fluid surrounding cultured cells) and they are fillable," said Yuan Wan, postdoctoral fellow in , Penn State. "However, there are two problems using them for cancer treatment. There aren't enough nanovesicles produced in short timescales and they do not have targeting effect."

The researchers developed an approach and platform to create large amounts of fillable and targeted nanovesicles. They report their results in a recent issue of Cancer Research.

To create targeted nanovesicles, ligands—perhaps short pieces of protein—need to be attached to the nanovesicle wall so they can recognize . The process for making targeted nanovesicles now requires using viruses to insert relevant DNA fragments into the genome of the and then collecting ligand-bearing nanovesicles released from the gene-modified cells.

Yuan, working with Si-Yang Zheng, associated professor of biomedical engineering, developed a simpler and faster method for attaching ligands. The researchers chemically graft the lipid-tagged ligands onto the cell membrane. They do this before they pass the cells through a sieve, which converts the cell membranes into millions of vesicles bearing ligands that can be filled with an appropriate drug to target the cancer.

"Pushing the cells through a filter is the engineered way to produce lots of nanovesicles," said Zheng.

The researchers used mouse autologous immune cells and created the ligand-targeted, fillable nanovesicles in the laboratory. They then infused these drug-loaded nanovesicles into the original mouse to treat tumors.

"This approach enables us to create nanovesicles with different ligands targeting different types of tumors in about 30 minutes to meet actual needs," said Zheng. "With this approach, we also can put different types of ligands on a nanovesicle. We could have one ligand that targets while another ligand says, 'don't eat me.'"

Zheng is referring to the body's propensity to clear materials that do not belong from the blood stream. If a nanovesicle has a attached that suggests the vesicle is autologous, then the vesicle, and its drug payload, might remain in circulation longer, making it more successful in finding and killing the target cancer cells.

The researchers believe that a variety of other cells, including , T cells—cells of the immune system—and other cell types could be modified and used as donor for extrusion of nanovesicles.

Explore further: 'Decorated' stem cells could offer targeted heart repair

Related Stories

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Tiny 'garbage collectors' help control brain development

February 19, 2014
(Medical Xpress)—Millions of tiny nanovesicles—once thought to be merely molecular garbage collectors—are actually stuffed with information crucial to brain development, Yale researchers report.

Researchers discover biomarker, potential targeted therapy for pancreatic cancer

October 4, 2013
University of Cincinnati (UC) researchers have discovered a biomarker, known as phosphatidylserine (PS), for pancreatic cancer that could be effectively targeted, creating a potential therapy for a condition that has a small ...

Recommended for you

Researchers identify compound to prevent breast cancer cells from activating in brain

March 22, 2018
Researchers at Houston Methodist used computer modeling to find an existing investigational drug compound for leukemia patients to treat triple negative breast cancer once it spreads to the brain.

Could a pap test spot more than just cervical cancer?

March 22, 2018
Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early.

Three-in-one molecule shows promise in helping certain breast cancer patients

March 22, 2018
A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, scientists report.

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...

Targeting telomeres to overcome therapy resistance in advanced melanoma

March 21, 2018
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. ...

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.